Insulin lispro (Lyumjev) vs THDB0206

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Insulin receptor · full Type 2 Diabetes pipeline

Insulin lispro (Lyumjev)

Marketed by Eli Lilly

Approved in Type 2 Diabetespeptide
Partial signal

NCT03214380 · Phase 3 · completed

The study randomized and double-blinded participants to LY900014 or insulin lispro, with 933 enrolled and approximately 336-337 participants in the main comparison arms. The primary HbA1c endpoint met the prespecified non-inferiority margin, but HbA1c is a laboratory surrogate rather than a hard clinical endpoint, supporting a moderate evidence grade.

Reported efficacy

Change From Baseline in Hemoglobin A1c (HbA1c) (Baseline, Week 26): Change From Baseline in Hemoglobin A1c (HbA1c) (Baseline, Week 26): LY900014 -0.56 Percentage of HbA1c (Standard Error 0.046) vs Insulin Lispro (Humalog) -0.63 Percentage of HbA1c (Standard Error 0.061) (met)

Result source: NCT03952143

THDB0206

Developed by Adocia and partners

Phase 3 in Type 2 Diabetespeptide
Partial signal

NCT05834868 · Phase 3 · completed

The study was randomized and actively controlled with insulin lispro, but it was open-label and used change in HbA1c as its primary, surrogate endpoint rather than a hard clinical outcome. Registry results are not posted; the sponsors (Adocia and Tonghua Dongbao) announced positive topline results versus Humalog in July 2025, so the result rests on a company announcement.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

No aligned efficacy figure on record for this race.

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointInsulin lispro (Lyumjev)THDB0206
HbA1c, change-0.4% vs -0.4%vs Insulin Lispro (Humalog)wk 26 · n 334NCT03214380
1 other result
  • -0.6% vs -0.6% wk 26 · n 388 · Phase 3 · primary NCT03952143
—Not posted · NCT05834868
Body weight, change (kg)—Not reported—Not posted · NCT05834868
HbA1c below 7%—Not reported—Not posted · NCT05834868
Fasting plasma glucose, change—Not reported—Not posted · NCT05834868
3-point MACE (% with event)—Not reported—Not posted · NCT05834868

HbA1c, change

Insulin lispro (Lyumjev)
-0.4% vs -0.4%vs Insulin Lispro (Humalog)wk 26 · n 334NCT03214380
1 other result
  • -0.6% vs -0.6% wk 26 · n 388 · Phase 3 · primary NCT03952143
THDB0206
—Not posted · NCT05834868

Body weight, change (kg)

Insulin lispro (Lyumjev)
—Not reported
THDB0206
—Not posted · NCT05834868

HbA1c below 7%

Insulin lispro (Lyumjev)
—Not reported
THDB0206
—Not posted · NCT05834868

Fasting plasma glucose, change

Insulin lispro (Lyumjev)
—Not reported
THDB0206
—Not posted · NCT05834868

3-point MACE (% with event)

Insulin lispro (Lyumjev)
—Not reported
THDB0206
—Not posted · NCT05834868
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

THDB0206: no structured comparison results are available for Type 2 Diabetes.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Insulin lispro (Lyumjev): 4 of 4 rows · THDB0206: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricInsulin lispro (Lyumjev)
Dropout rate
—a
NCT03214380 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 16 more results
—
NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3
17.6%
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3
—LY900014 After Meal
NCT03341312 · Phase 1 · registry result, not featured evidence
—LY900014 Before Meal
NCT03341312 · Phase 1 · registry result, not featured evidence
—15 U
NCT03286751 · Phase 1 · registry result, not featured evidence
—30 U
NCT03286751 · Phase 1 · registry result, not featured evidence
—7 U
NCT03286751 · Phase 1 · registry result, not featured evidence
—15 U
NCT03305822 · Phase 1 · registry result, not featured evidence
—15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
—15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
—15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
—15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
—LY900014 - Test (Part B)
NCT02703337 · Phase 1 · registry result, not featured evidence
—LY900014 - Test +15 Min (Part A)
NCT02703337 · Phase 1 · registry result, not featured evidence · combination
—LY900014 - Test -15 Min (Part A)
NCT02703337 · Phase 1 · registry result, not featured evidence
—LY900014 - Test 0 Min (Part A)
NCT02703337 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—a
NCT03214380 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 16 more results
—
NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.7%
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3
—LY900014 After Meal
NCT03341312 · Phase 1 · registry result, not featured evidence
—LY900014 Before Meal
NCT03341312 · Phase 1 · registry result, not featured evidence
—15 U
NCT03286751 · Phase 1 · registry result, not featured evidence
—30 U
NCT03286751 · Phase 1 · registry result, not featured evidence
—7 U
NCT03286751 · Phase 1 · registry result, not featured evidence
—15 U
NCT03305822 · Phase 1 · registry result, not featured evidence
—15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
—15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
—15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
—15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
—LY900014 - Test (Part B)
NCT02703337 · Phase 1 · registry result, not featured evidence
—LY900014 - Test +15 Min (Part A)
NCT02703337 · Phase 1 · registry result, not featured evidence · combination
—LY900014 - Test -15 Min (Part A)
NCT02703337 · Phase 1 · registry result, not featured evidence
—LY900014 - Test 0 Min (Part A)
NCT02703337 · Phase 1 · registry result, not featured evidence
Serious AEs
7.7%a
NCT03214380 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 16 more results
8.4%
NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.7%
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3
0%LY900014 After Meal
NCT03341312 · Phase 1 · registry result, not featured evidence
0%LY900014 Before Meal
NCT03341312 · Phase 1 · registry result, not featured evidence
0%15 U
NCT03286751 · Phase 1 · registry result, not featured evidence
0%30 U
NCT03286751 · Phase 1 · registry result, not featured evidence
0%7 U
NCT03286751 · Phase 1 · registry result, not featured evidence
0%15 U
NCT03305822 · Phase 1 · registry result, not featured evidence
0%15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
0%15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
0%15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
0%15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
0%LY900014 - Test (Part B)
NCT02703337 · Phase 1 · registry result, not featured evidence
0%LY900014 - Test +15 Min (Part A)
NCT02703337 · Phase 1 · registry result, not featured evidence · combination
0%LY900014 - Test -15 Min (Part A)
NCT02703337 · Phase 1 · registry result, not featured evidence
0%LY900014 - Test 0 Min (Part A)
NCT02703337 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
a
nasopharyngitis 14%
upper respiratory tract infection 8%
diarrhoea 3.3%
NCT03214380 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 15 more results
upper respiratory tract infection 5.3%
NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3
injection site reaction 5.6%
NCT03341312 · Phase 1 · registry result, not featured evidence
injection site reaction 2.9%
NCT03341312 · Phase 1 · registry result, not featured evidence
15 U
headache 10%
nausea 5%
injection site reaction 2.5%
NCT03286751 · Phase 1 · registry result, not featured evidence
30 U
headache 14.6%
injection site reaction 14.6%
nausea 7.3%
NCT03286751 · Phase 1 · registry result, not featured evidence
7 U
headache 15%
injection site reaction 2.5%
nausea 2.5%
NCT03286751 · Phase 1 · registry result, not featured evidence
15 U
headache 5.3%
vessel puncture site thrombosis 5.3%
NCT03305822 · Phase 1 · registry result, not featured evidence
15 U
infusion site pain 12%
catheter site bruise 8%
vessel puncture site bruise 8%
NCT03232983 · Phase 1 · registry result, not featured evidence
15 U
injection site pain 11.5%
application site erythema 7.7%
catheter site bruise 7.7%
NCT03232983 · Phase 1 · registry result, not featured evidence
15 U
catheter site pain 10.7%
catheter site swelling 7.1%
application site erythema 3.6%
NCT03232983 · Phase 1 · registry result, not featured evidence
15 U
catheter site bruise 7.7%
infusion site erythema 7.7%
infusion site swelling 7.7%
NCT03232983 · Phase 1 · registry result, not featured evidence
headache 6.7%
back pain 0%
thrombophlebitis 0%
NCT02703337 · Phase 1 · registry result, not featured evidence
back pain 0%
headache 0%
thrombophlebitis 0%
NCT02703337 · Phase 1 · registry result, not featured evidence · combination
thrombophlebitis 6.9%
back pain 0%
headache 0%
NCT02703337 · Phase 1 · registry result, not featured evidence
thrombophlebitis 10.3%
back pain 0%
headache 0%
NCT02703337 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 14 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Insulin lispro (Lyumjev)

HbA1c -0.38% (n=334) vs -0.43% (n=335) Insulin Lispro (Humalog) @ 26wk
absolute change · percentage points
NCT03214380 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 1 more result
-0.56% (n=388) vs -0.63% (n=198) Insulin Lispro (Humalog) @ 26wk
NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3
HbA1c 7.0 or Less 58.2% (n=316) vs 52.5% (n=320) Insulin Lispro (Humalog) @ 26wk
event count · % of participants
NCT03214380 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 184 Participants as posted
PPG 1H Excursion mg/dL 86.2 vs 100.8 Insulin Lispro (Humalog) mg @ 26wk
absolute value · mg
NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3
PPG 2 h Excursion mg/dL 6.18 vs 7.39 Insulin Lispro (Humalog) mmol/L @ 26wk
absolute value · mmol/L
NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from 111.4 mg/dL as posted
HbA1c Less Than 7% 46.65% (n=358) vs 44.5% (n=191) Insulin Lispro (Humalog) @ 26wk
responder rate · % of participants
HbA1c < 7%
NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3
HbA1c 6 5 or Less 27.93% (n=358) vs 27.23% (n=191) Insulin Lispro (Humalog) @ 26wk
responder rate · % of participants
HbA1c ≤ 6.5%
NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3
Time in Range Daytime 3.8 % of time @ 12wk
absolute change · % of time
No placebo or comparator arm
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3
HbA1c -0.44% (n=167) @ 12wk
absolute change · percentage points
No placebo or comparator arm
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3
Time in Range 24 h 3.3 % of time @ 12wk
absolute change · % of time
No placebo or comparator arm
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3
Time Below 54 0 % of time @ 12wk
absolute change · % of time
No placebo or comparator arm
24-hour Period
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3
Time Above 180 -3.4 % of time @ 12wk
absolute change · % of time
No placebo or comparator arm
24-Hour Period
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3
Time Above 2.50 -1.07 % of time @ 12wk
absolute change · % of time
No placebo or comparator arm
24-Hour Period
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3

+ 8 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Insulin lispro (Lyumjev)'s landscape · THDB0206's landscape